



**Risk of tuberculosis among people with diabetes mellitus:  
A National Cohort Study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000666
Article Type:	Research
Date Submitted by the Author:	22-Nov-2011
Complete List of Authors:	Dobler, Claudia; Woolcock Institute of Medical Research, The University of Sydney; Liverpool Hospital, Department of Respiratory Medicine Flack, Jeffrey; Diabetes Centre, Bankstown-Lidcombe Hospital Marks, Guy; Woolcock Institute of Medical Research, The University of Sydney; Liverpool Hospital, Department of Respiratory Medicine
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Public health, Respiratory medicine, Diabetes and endocrinology, Global health
Keywords:	Tuberculosis < INFECTIOUS DISEASES, General diabetes < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Respiratory infections < THORACIC MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

# Risk of tuberculosis among people with diabetes mellitus:

## A National Cohort Study

Claudia C Dobler<sup>1,2</sup>, Jeffrey R Flack<sup>3</sup>, Guy B Marks<sup>1,2</sup>

1. Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, University of Sydney, Australia
2. Department of Respiratory Medicine, Liverpool Hospital, Sydney, Australia
3. Diabetes Centre, Bankstown-Lidcombe Hospital, Sydney, Australia

Correspondence to: [cdobler@med.usyd.edu.au](mailto:cdobler@med.usyd.edu.au)

Short Title: Tuberculosis in diabetes

Key words: tuberculosis, diabetes mellitus, relative risk, data linkage

Word count: 2,968

## Abstract

**Objective** Previous studies that have found an increased risk for tuberculosis (TB) in people with diabetes mellitus (DM) have been conducted in segments of the population and have not adjusted for important potential confounders. We sought to determine the relative risk for TB in the presence of DM in a national population with data on confounding factors.

**Design** Whole population historical cohort study

**Setting** All Australian States and Territories with a mean TB incidence of 5.8/100,000

**Participants** Cases of TB in people with DM were identified by record linkage using the National Diabetes Services Scheme database and TB notification databases for the years 2001 to 2006.

**Primary and secondary outcome measures** Primary outcome was notified cases of TB. Secondary outcome was notified cases of culture-confirmed TB. Relative risk of TB was estimated with adjustment for age, sex, TB incidence in country of birth and indigenous status.

**Results** There were 6276 cases of active TB among 19,855,283 people living in Australia between 2001 and 2006. There were 271 (188 culture positive) cases of TB among 802,087 members of the DM cohort and 130 cases of TB among 273,023 people using insulin. The crude relative risk (RR) of TB was 1.78 (95% CI 1.17 to 2.73) in all people with DM and 2.16 (95% CI 1.19 to 3.93) in people with DM using insulin. The adjusted relative risks were 1.48 (95% CI 1.04 to 2.10) and 2.27 (95% CI 1.41 to 3.66), respectively.

**Conclusions** The presence of DM alone does not justify screening for latent tuberculosis infection (LTBI). However, when combined with other risk factors for TB, the presence of DM may be sufficient to justify screening and treatment for LTBI.

## Article Summary

### Article focus

- National, general population-based, historical cohort study to estimate the risk of tuberculosis among people with diabetes mellitus.
- Adjustment for important potentially confounding risk factors including age, sex, indigenous status, and tuberculosis incidence in country of birth.

### Key messages

- Overall, people with diabetes mellitus have a 1.5 fold increased risk of developing tuberculosis.
- The risk for tuberculosis is higher among people who are using insulin for diabetes mellitus.
- Diabetes mellitus accounts for a small proportion of cases of tuberculosis in a low tuberculosis incidence setting.

### Strengths and limitations of this study

- The strengths of this study are the cohort design, the large population size, the general population base for the study cohort and the adjustment for important potential confounders, especially TB incidence in the country of birth.
- The study limitations are the unavailability of laboratory results to indicate if blood glucose levels were well or poorly controlled in people with diabetes mellitus and the

1  
2  
3 inability to reliably distinguish between type 1 and type 2 diabetes mellitus in this  
4  
5 data source.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction

Tuberculosis (TB) continues to be a major global health problem. It is estimated that one-third of the world's population have TB infection and there are 9.4 million new cases of TB per year.<sup>1</sup> Major impairment of cell-mediated immunity, such as occurs in HIV infection, leads to a dramatic increase in the risk of developing TB.<sup>2</sup> A lesser degree of impairment of immune function, such as occurs in patients with rheumatic diseases who are on moderate-to-high dose steroid treatment, has also been found to be associated with an increased TB risk.<sup>3</sup> Diabetes mellitus (DM) is a common chronic disease associated with impaired immune function. Cohort and case control studies have shown an association between DM and TB.<sup>4-9</sup> With the rising prevalence of DM in countries where TB is endemic, there has been renewed interest in the question of whether DM increases the risk of active TB, and thus could significantly add to the worldwide burden of disease.

A systematic review and meta-analysis from 2008 identified only three cohort studies examining the risk of TB in patients with DM.<sup>10</sup> Two of these were conducted in renal transplant recipients, who had another powerful cause of immunosuppression.<sup>11-12</sup> The one general population cohort study in this review, conducted among South Korean civil servants, did identify an increased risk of TB among people with DM.<sup>5</sup> The meta-analysis also included several case-control studies. However, most of these studies have not measured and controlled adequately for potential major confounders.<sup>10</sup> Hence, the findings of these case-control studies, and the meta-analysis summarising them, may not be a valid reflection of the true risk of TB in association with DM. Another cohort study, also from East Asia but not included in the meta-analysis, found that DM was associated with a modest increase in the risk of active, culture-confirmed, and pulmonary TB, with adjusted hazard ratios of 1.8, 1.9

1  
2  
3 and 1.9 respectively.<sup>4</sup> An English study published in 2010 found a two- to threefold  
4  
5 increased risk of TB among patients admitted to hospital because of diabetes<sup>9</sup>.  
6  
7

8  
9  
10 With the growing epidemic of obesity and DM worldwide and continued high prevalence of  
11  
12 TB in low-income countries,<sup>13-14</sup> it is important to obtain further data on the relative risk of  
13  
14 TB in DM. We conducted a national, general population historical cohort study to estimate  
15  
16 the risk of TB among people with DM with adjustment for important potentially confounding  
17  
18 risk factors.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Setting and cohort

We conducted a national, general population historical cohort study among all 19.9 million residents of Australia, 802,087 (4.0%) of whom were registered with the National Diabetes Services Scheme (NDSS). Australia has a low incidence of TB (5.8 per 100,000 population) and 86% of all TB cases occur in overseas-born people.<sup>15</sup> All TB treatment is provided free of charge.

### Description of data sources and data linkage

#### National Diabetes Services Scheme

People with DM were identified using the National Diabetes Services Scheme (NDSS) database. The NDSS is a subsidy scheme operated by Diabetes Australia Ltd for the Australian Government. People who are registered with the NDSS can access a range of products including blood and urine testing strips, syringes, needles and insulin pump consumables at a concessional price. In order to register with the NDSS, an individual must receive certification of a diagnosis of DM and, if relevant, the need for insulin therapy, from a doctor or credentialed diabetes educator.<sup>16</sup> Access to diagnostic services is enhanced by the existence of a universal health insurance system which gives access to primary care and other health services free-of-charge or at low cost to all. People with all types of diabetes mellitus (type 1, type 2, gestational diabetes) are eligible for registration with the NDSS. Diabetes type is self-reported by the patients at the time of registration and confirmed by a health professional. We included all subjects into the analyses that were registered with the NDSS between January 2001 and December 2006 except those with gestational diabetes. Data on names, sex, State or Territory of usual residence, date of birth, country of birth, indigenous



1  
2  
3 status and insulin use were extracted and sent to the database manager who performed the  
4  
5 data linkage (see below).  
6  
7  
8

### 9 10 **State and Territory TB notification databases**

11 Notification of TB is compulsory in Australia as this notification initiates public health  
12  
13 investigation and action. All TB cases are collected at State and Territory level. We used the  
14  
15 State and Territory TB notification databases to identify patients with TB. All subjects that  
16  
17 were notified for active TB disease to one of the State or Territory TB notification databases  
18  
19 between January 2001 and December 2006 were included in our analyses. Data on names,  
20  
21 date of notification, date of birth, sex, country of birth, indigenous status and TB culture  
22  
23 results were extracted for this analysis.  
24  
25  
26  
27  
28

### 29 30 **Data linkage**

31 People with DM who had an episode of active TB were identified by record linkage using the  
32  
33 NDSS database and the State and Territory TB notification databases from January 2001 to  
34  
35 December 2006. The linkage was performed at the Australian Institute of Health and Welfare  
36  
37 (AIHW). From the two datasets, match files were created containing a unique record  
38  
39 identifier, the data linkage items (surname, given names and date of birth) and the data  
40  
41 linkage check items (sex, country of birth, state/territory of residence). From each of the  
42  
43 original datasets, analysis files were created containing the unique record identifier and all the  
44  
45 data fields required for analysis. Each of the analysis files was then linked to the match files  
46  
47 and the record identifiers were removed from these analysis files. The data linkage also  
48  
49 allowed exclusion of duplicate data on the same patient. The data linkage protocol from the  
50  
51 AIHW has been published online.<sup>17</sup>  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Census data for the general population

Estimates for the distribution of age group, country of birth, sex, and indigenous status in the general population were obtained from the Australian Bureau of Statistics based on census data for 2006.

### Sample size and study power

The annual incidence of TB in Australia is 5.8 per 100,000. Hence, over six years, the expected cumulative incidence is 35 per 100,000. The study population is the entire population of Australia, that is, 20 million people. We estimated that there were 1,000,000 persons with diabetes. The study had 80% power to detect a relative risk of 1.16 or higher.

### Statistical analysis

Only cases of TB that were notified after DM was diagnosed were included. The follow-up period started from 1/1/2001 or the date of DM diagnosis, whichever was the later and continued until 31/12/2006 or the date of diagnosis of TB, whichever was the earlier. TB incidence rates were expressed per 100,000 person years of follow up with asymptotic 95% confidence intervals.<sup>20</sup>

The relative risk of TB in patients with DM was estimated using a log-binomial model with correction for overdispersion and adjustment for TB incidence in country of birth, sex, age and indigenous status. Individual level data on these potential confounders were available for the DM and TB cohorts. For the general population aggregate population data for these covariates were obtained from the Australian Bureau of Statistics in the form of a contingency table containing population numbers cross-classified by all possible combinations of strata of the covariates listed above. Age was classified into 5 year age

1  
2  
3 groups and country of birth was aggregated to groupings of countries with a similar incidence  
4  
5 of TB (<10, 10-24, 25-49, 50-99, 100-299, and  $\geq 300$  per 100,000) based on published World  
6  
7 Health Organization data.<sup>18</sup>  
8  
9

10  
11  
12 Population attributable fraction was estimated using the formula:  $(Pe * (RR - 1)) / ((Pe * (RR$   
13  
14  $- 1) + 1)$  where RR is the relative risk, estimated as above, and Pe is the proportion of the  
15  
16 population exposed to the risk factor, that is, the prevalence of DM in the population.<sup>19</sup>  
17  
18

19  
20  
21 We performed planned sub-group analyses based on insulin treatment status and TB culture  
22  
23 status. In addition, interactions between DM status and age, sex, indigenous status, and TB  
24  
25 incidence in country of birth were tested.  
26  
27

28  
29  
30 All statistical analyses were carried out using SAS Statistical Software (Version 9.2) (SAS  
31  
32 Institute, Cary, NC, USA).  
33  
34

### 35 36 **Ethical approval**

37  
38 The study protocol was approved by the Sydney South West Area Health Service Human  
39  
40 Research Ethics Committee - Western Zone, the New South Wales Population & Health  
41  
42 Services Research Ethics Committee, the Australian Institute of Health and Welfare Ethics  
43  
44 Committee, the Queensland Health Research Ethics & Governance Unit, the Department of  
45  
46 Human Services Victoria Research Governance, the Australian Capital Territory Health  
47  
48 Human Research Ethics Committee, the Department of Health Western Australia Human  
49  
50 Research Ethics Committee, the Tasmania Health and Medical Human Research Ethics  
51  
52 Committee, the South Australia Department of Health Human Research Ethics Committee  
53  
54 and the Northern Territory Human Research Ethics Committee. The requirement for written  
55  
56  
57  
58  
59  
60

1  
2  
3 or verbal patients' consent for this data linkage study was waived by all of the above ethics  
4  
5 committees because existing data sources were used.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Results

The study population comprised 19,855,283 residents of Australia, 802,087 (4%) of whom were registered with the NDSS including 273,023 (1.4%) with DM who were using insulin.

Characteristics of the DM population, the general population, the TB population and the DM population with TB are shown in Table 1. The percentage of Australian-born people was slightly higher in the DM population than in the general population (74% versus 71%) and more people came from an area with a TB incidence below 25 / 100,000 (92% versus 84%). The mean duration of follow-up was 4.6 years.

There were 6,276 TB notifications (5.7/100,000 per year, 95% CI 5.5 to 5.8) in Australia during the study period (Table 2). There were 271 cases of TB among 802,087 members of the DM cohort (7.4/100,000 per year, 95% CI 6.5 to 8.3). Of these, 188 (69%) were culture positive, which is similar to the 70% culture positive cases among all TB notifications. There were 130 TB notifications among 273,023 people using insulin (9.1 per 100,000 per year, 95% CI 7.6 to 10.9).

The crude relative risk (RR) of TB was 1.78 (95% CI 1.17 to 2.73) in all people with DM and 2.16 (95% CI 1.19 to 3.93) in people with DM using insulin. In the multivariate analysis adjusted for age, TB incidence in country of birth, indigenous status and sex, the relative risk (aRR) of TB was 1.48 (95% CI 1.04 to 2.10) in all people with DM and 2.27 (95% CI 1.41 to 3.66) in people using insulin (Table 3). The estimates of relative risk were slightly higher when the analysis was limited to culture-confirmed cases of TB (Table 3).

The relative risks were not significantly modified by age group, indigenous status, sex or incidence in country of birth (all P values for interaction > 0.25).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The population attributable fraction of DM for TB was 1.7%, based on a diabetes prevalence of 3.6%

For peer review only

## Discussion

In this large, population-based cohort study conducted in 19.9 million residents of Australia with adjustment for important confounding factors, we found that, overall, people with DM have a 1.5 fold increased risk of developing TB. Those who are using insulin for DM have a greater risk. We also found that the population attributable fraction of DM for TB was very small.

The results of our study extend the findings of previous studies, which have also observed an increased risk for TB in patients with DM. A cohort study in Hong Kong, limited to people aged 65 years or more, found an adjusted hazard ratio (aHR) of 1.77 (95% CI 1.41-2.24) for active TB, and an aHR of 1.91 (95% CI 1.45-2.52) for culture-confirmed TB among patients with DM.<sup>4</sup> However, this study found that people with diagnosed DM and with haemoglobin HbA1c <7% at enrolment were not at increased risk of TB (aHR 0.68, 95% CI 0.33 to 1.36). A Korean cohort study conducted in 790,000 civil servants found a RR of 3.47 (95% CI 2.98 to 4.03) for pulmonary TB in people with DM (and a RR of 5.15 for culture confirmed cases, 95% CI 3.82 to 6.94).<sup>5</sup> In the Korean study, a diagnosis of DM was based solely on blood glucose levels. Thus, it did not include diabetic subjects who were euglycaemic at the time of screening. In their systematic review on thirteen observational studies on the risk of DM in TB, Jeon et al. found that studies which used laboratory testing as the basis for the diagnosis of DM had a higher RR for TB than those that used self reporting or medical records (RR of 3.89, 2.26, and 1.61, respectively).<sup>10</sup> If blood glucose levels are used for the definition of DM patients with diabetes who have well controlled glucose levels are less likely to be included. These findings imply that hyperglycaemia, rather than a DM diagnosis per se, increases the risk of developing active TB. In our study, DM diagnosis was based on self reporting confirmed by a health professional, and laboratory results were not available. As insulin use

1  
2  
3 is often a marker of longer duration and/or poorly controlled (type 2) DM, our finding that  
4  
5 insulin users had a higher TB risk than the whole diabetes cohort, would support the  
6  
7 assumption that hyperglycaemia increases the risk for developing active TB. However, as we  
8  
9 did not have any data on duration of DM or HbA1C levels, and people with type I diabetes  
10  
11 were included in the insulin treated group, it remains unclear whether insulin use is an  
12  
13 independent risk factor for TB or a proxy for longer duration or greater severity of DM.  
14  
15

16  
17  
18 Age did not modify the effect of DM on risk of TB in our study. Two published studies have  
19  
20 demonstrated stronger associations of DM with TB among people aged less than 40 years  
21  
22 compared with older people<sup>5, 8</sup> In these studies the definition of DM cases was based on  
23  
24 laboratory results. Another study, which had a DM diagnosis based on medical records, did  
25  
26 not show the same trend for age.<sup>24</sup>  
27  
28

29  
30  
31 Interestingly, there is some evidence that the strength of the association of DM and TB  
32  
33 increases with increasing background TB incidence in the study population<sup>7 10</sup>. This trend  
34  
35 was found in a systematic review on the risk of TB in DM in 13 observational studies<sup>10</sup>, and  
36  
37 in a Texan study that found that the association was stronger for the population in the Texas  
38  
39 border region, where there are higher incidence rates of TB, compared with non-border  
40  
41 counties.<sup>7</sup> The reason for this observation is not entirely clear, but it could well relate to the  
42  
43 level of glucose control in patients with DM in settings with a high TB incidence.  
44  
45  
46  
47  
48

49  
50 The strengths of our study are the cohort design, the large population size and the general  
51  
52 population base for the study cohort. We believe that the diabetes cohort represents a  
53  
54 virtually complete cohort of patients with diabetes in Australia. The Australian Diabetes,  
55  
56 Obesity and Lifestyle Study (1999-2000), which included previously undiagnosed cases  
57  
58  
59  
60



1  
2  
3 identified by blood glucose estimations, estimated that 950,000 persons aged 25 years and  
4  
5 over had diabetes<sup>23</sup>. The National Health Survey 2004-05 found that 700,000 (3.6%)  
6  
7 Australians identified themselves as having DM. <sup>22</sup> In the same period, 733,000 (3.6%)  
8  
9 Australians with a certified diagnosis of DM were registered with the NDSS.<sup>22</sup> On the basis  
10  
11 of these and other data, Diabetes Australia estimates that the NDSS covers 80%–90% of  
12  
13 people with diagnosed DM <sup>22</sup>. The Australian Institute of Health and Welfare (AIHW) has  
14  
15 identified the NDSS as one of the best available sources for monitoring the prevalence of  
16  
17 diagnosed DM in Australia, based on coverage of the DM population, currency of the data  
18  
19 source, and frequency of updates to the data source <sup>22</sup>.  
20  
21  
22  
23  
24

25 An additional strength of this study is the adjustment for important potential confounders,  
26  
27 especially for the TB incidence in the country of birth. The incidence of TB in the country of  
28  
29 birth is one of the strongest predictors of the risk of developing TB, but none of the  
30  
31 previously published studies had adjusted the RR for this important confounder.<sup>10</sup> This  
32  
33 adjustment is especially important for low TB incidence settings, where the majority of TB  
34  
35 cases usually occur in foreign-born people.<sup>21</sup> The adjustment for TB incidence in country of  
36  
37 birth also makes the study results generalizable to populations with varying incidence of TB.  
38  
39  
40  
41  
42

43 Our study has some limitations. As outlined above, laboratory results were not available to  
44  
45 indicate if blood glucose levels were well or poorly controlled in people with DM. However,  
46  
47 the diagnosis of DM in this study population is robust as all individuals registered with the  
48  
49 NDSS must receive certification of a diagnosis of DM by a doctor or a credentialed diabetes  
50  
51 educator. The available data did not allow us to reliably distinguish between type 1 and type  
52  
53 2 DM. It did allow us to reliably distinguish between patients treated with insulin and those  
54  
55 not treated with insulin.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 A limitation that this study shares with previously published papers in this area is that we did  
6  
7 not have any information on treatment of latent tuberculosis infection in the NDSS cohort.

8  
9  
10 However, routine assessment and treatment for latent tuberculosis infection in patients with  
11  
12 diabetes is currently not recommended in Australia, and it can therefore be assumed that most  
13  
14 people with diabetes would not have been assessed and treated for latent tuberculosis  
15  
16 infection.  
17

### 18 19 20 21 **Conclusions**

22  
23 DM is associated with a modest increase in the risk of developing TB. The risk is greater  
24  
25 among those treated with insulin for diabetes. Based on this modest relative risk, the presence  
26  
27 of DM alone does not justify screening for, and treatment of, latent tuberculosis infection  
28  
29 (LTBI). However, when combined with other risk factors for TB, the presence of DM may be  
30  
31 sufficient to justify screening and treatment for LTBI. The low population attributable risk, at  
32  
33 least in Australia, suggests that control of TB in people with DM is unlikely to make a major  
34  
35 contribution to the burden of TB in the population.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments

We acknowledge Mark Short, PhD, BSc (Hons) and David Meere, BSc, from the Australian Institute of Health and Welfare for performing the database linkage. We also acknowledge the numerous people who have contributed to the collection of TB notifications and the maintenance of TB notification databases in all Australian States and Territories and the National Diabetes Services Scheme which granted us access to their database.

## Financial disclosure

The study was funded by a grant from the Sydney South West Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Author contributions

All authors were involved in study concept and design, acquired data, revised the manuscript for important content, and approved the final manuscript. CCD drafted the initial manuscript. GBM performed the statistical analysis.

## Competing interests

No conflict of interest reported.

## Data sharing statement

There is no additional data available.

## Trial registration

Trial registration was not required, as this was a historical cohort study

## References

1. World Health Organization. Global tuberculosis control: WHO report. 2010. [http://www.who.int/tb/publications/global\\_report/2010/en/index.html](http://www.who.int/tb/publications/global_report/2010/en/index.html) Accessed November 11, 2011.
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* 2003;163:1009-1021.
3. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. *Clin Exp Rheumatol* 1998;16:9-13.
4. Leung CC, Lam TH, Chan WM, Yew WW, et al. Diabetic control and risk of tuberculosis: a cohort study. *Am J Epidemiol* 2008;167:1486-1494.
5. Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. *Tuber Lung Dis* 1995;76:529-533.
6. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. *Am J Public Health* 1997;87:574-579.
7. Perez A, Brown HS, 3rd, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. *Am J Trop Med Hyg* 2006;74:604-611.
8. Ponce-De-Leon A, Garcia-Garcia Md MdL, Garcia-Sancho MC, et al. Tuberculosis and diabetes in southern Mexico. *Diabetes Care* 2004;27:1584-1590.
9. Young F, Wotton CJ, Critchley JA, et al. Increased risk of tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. *J Epidemiol Community Health* 2010 (epub ahead of print).
10. Jeon CY, Murray MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. *PLoS Med* 2008;5:e152.
11. Chen CH, Lian JD, Cheng CH, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. *Transpl Infect Dis* 2006;8:148-156.
12. John GT, Shankar V, Abraham AM, et al. Risk factors for post-transplant tuberculosis. *Kidney Int* 2001;60:1148-1153.
13. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 2009;301:2129-2140.
14. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;9:737-746.

15. Barry C, Konstantinos A. Tuberculosis notifications in Australia, 2007. *Commun Dis Intell* 2009;33:304-315.
16. Process for Registration with the NDDS. <http://www.ndss.com.au/>. Accessed November 11, 2011.
17. AIHW. Data linkage and protecting privacy: a protocol for linking between two or more data sets held within the Australian Institute of Health and Welfare. [http://www.aihw.gov.au/dataonline/aihw\\_privacy\\_protection\\_protocols\\_data\\_linkage.pdf](http://www.aihw.gov.au/dataonline/aihw_privacy_protection_protocols_data_linkage.pdf) Accessed November 11, 2011.
18. World Health Organization. Global Tuberculosis database. <http://apps.who.int/globalatlas/dataQuery/default.asp> Accessed November 11, 2011.
19. Walter SD. Calculation of attributable risks from epidemiological data. *Int J Epidemiol* 1978;7:175-182.
20. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981. p. 14-5.
21. Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. *JAMA* 2008;300:405-412.
22. Australian Institute of Health and Welfare 2009. Diabetes prevalence in Australia: an assessment of national data sources. Diabetes series no. 14. Cat. no. CVD 46. Canberra: AIHW. <http://www.aihw.gov.au/publications/index.cfm/title/10639>. Accessed November 11, 2011.
23. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care* 2002;25:829-834.
24. Dyck RF, Klomp H, Marciniuk DD, et al. The relationship between diabetes and tuberculosis in Saskatchewan: comparison of registered Indians and other Saskatchewan people. *Can J Public Health* 2007;98:55-59.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Tables**

**Table 1.** Characteristics of the general population, the DM population, the TB population and the TB in DM population

Variable	General population excluding people with diabetes (n=19,053,196)	DM population (n=802,087)	TB population (n=6,276)	TB in DM population (n=271)
<b>Gender, number (%)</b>				
Female	9,669,609 (51)	386,427 (48)	3045 (49)	122 (45)
Male	9,383,587 (49)	415,660 (52)	3231 (51)	149 (55)
<b>Age group in years, number (%)</b>				
<15	3,931,189 (21)	6,024 (1)	272 (4)	0
15-34	5,341,173 (28)	39,482 (5)	2220 (35)	10 (4)
35-54	5,526,963 (29)	173,391 (21)	1729 (28)	56 (21)
55-74	3,199,578 (17)	366,534 (46)	1176 (19)	123 (45)
≥ 75	1,054,293 (6)	216,656 (27)	879 (14)	82 (30)
<b>Country of origin, number (%)</b>				
Australian born	13,477,425 (71)	595,518 (74)	1212 (19)	131 (48)
born overseas	4,209,464 (22)	206,569 (26)	5064 (81)	140 (52)
unknown	1,366,307 (7)	0	0	0
<b>Indigenous status, number (%)</b>				
non-indigenous or not-stated	18,622,238 (98)	780,197 (97)	6072 (97)	265(98)
indigenous	430,958 (2)	21,890 (3)	204 (3)	6 (2)
<b>TB incidence in country of birth (per 100,000), number (%)</b>				
<25	16,052,757 (84)	739,423 (92)	1964 (31)	168 (62)
25-99	848,417 (4)	36,292 (5)	1350 (22)	44 (16)
≥100	728,119 (4)	26372 (3)	2962 (47)	59 (22)
unknown	1,423,903 (7)	0	0	0

**Table 2.** Incidence of tuberculosis in the general population and in people with diabetes

	Incidence of all TB per 100,000/year (95% confidence interval)		Incidence of culture positive TB per 100,000/year (95% confidence interval)	
	General population	People with diabetes	General population	People with diabetes
<b>All persons</b>	5.7 (5.5 to 5.8)	7.4 (6.5 to 8.3)	4.0 (3.9 to 4.1)	5.1 (4.4 to 5.9)
<b>Age, years</b>				
<15	1.2 (1.1 to 1.4)	0	0.4 (0.3 to 0.5)	0
15 to 34	7.4 (7.1 to 7.7)	6.1 (3.1 to 11.7)	5.5 (5.2 to 5.8)	4.3 (1.9 to 9.3)
35 to 54	5.5 (5.2 to 5.7)	7.5 (5.8 to 9.9)	3.9 (3.7 to 4.1)	5.5 (4.0 to 7.6)
55 to 74	6.0 (5.6 to 6.3)	7.4 (6.2 to 8.9)	4.1 (3.8 to 4.4)	4.9 (3.9 to 6.1)
≥ 75	13.0 (12.1 to 13.9)	7.5 (6.0 to 9.4)	9.7 (9.0 to 10.5)	5.4 (4.2 to 7.0)
<b>Sex</b>				
Male	5.9 (5.7 to 6.2)	7.9 (6.7 to 9.3)	4.3 (4.1 to 4.5)	5.4 (4.4 to 6.6)
Female	5.4 (5.2 to 5.6)	6.9 (5.7 to 8.3)	3.7 (3.6 to 4.9)	4.9 (3.9 to 6.0)
<b>TB incidence in country of birth</b>				
< 25 per 100,000	1.95 (1.86 to 2.04)	4.9 (4.2 to 5.7)	1.26 (1.20 to 1.34)	3.4 (2.8 to 4.1)
25-99 per 100,000	25.5 (24.1 to 26.9)	30.1 (22.1 to 40.8)	18.0 (16.9 to 19.2)	18.5 (12.4 to 27.3)
≥100 per 100,000	65.4 (63.1 to 67.8)	57.8 (44.4 to 75.0)	48.8 (46.8 to 50.9)	45.0 (33.3 to 60.6)

**Table 3.** Relative Risks (crude and adjusted) for different TB endpoints

Characteristics	Crude Relative Risk univariate analysis (95% CI)	p value	Adjusted Relative Risk <sup>a</sup> multivariate analysis (95% CI)	p value
All TB	1.78 (1.17 to 2.73)	0.008	1.48 (1.04 to 2.10)	0.03
Culture positive TB	1.83 (1.19 to 2.81)	0.006	1.49 (1.05 to 2.11)	0.02
All TB in insulin-users	2.16 (1.19 to 3.93)	0.01	2.27 (1.41 to 3.66)	0.0008
Culture positive TB in insulin-users	2.44 (1.37 to 4.34)	0.002	2.55 (1.62 to 4.01)	<0.001

a Adjusted for sex, age, indigenous status, TB incidence in country of birth



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9-10
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	Data linkage, not clinical trial
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Data linkage, not clinical trial
		(b) Give reasons for non-participation at each stage	See above
		(c) Consider use of a flow diagram	See above
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12+ Table1
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	12
Outcome data	15*	Report numbers of outcome events or summary measures over time	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12, Table 2+3
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Table 2
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	14
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	16-17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



**Risk of tuberculosis among people with diabetes mellitus:  
An Australian nationwide cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000666.R1
Article Type:	Research
Date Submitted by the Author:	27-Dec-2011
Complete List of Authors:	Dobler, Claudia; Woolcock Institute of Medical Research, The University of Sydney, ; Liverpool Hospital, Department of Respiratory Medicine Flack, Jeffrey; Diabetes Centre, Bankstown-Lidcombe Hospital, Marks, Guy; Woolcock Institute of Medical Research, The University of Sydney, ; Liverpool Hospital, Department of Respiratory Medicine,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Public health, Respiratory medicine, Diabetes and endocrinology, Global health
Keywords:	Tuberculosis < INFECTIOUS DISEASES, General diabetes < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Respiratory infections < THORACIC MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

# Risk of tuberculosis among people with diabetes mellitus:

## An Australian nationwide cohort study

Claudia C Dobler<sup>1,2</sup>, Jeffrey R Flack<sup>3</sup>, Guy B Marks<sup>1,2</sup>

1. Respiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, University of Sydney, Australia
2. Department of Respiratory Medicine, Liverpool Hospital, Sydney, Australia
3. Diabetes Centre, Bankstown-Lidcombe Hospital, Sydney, Australia

Correspondence to: [cdobler@med.usyd.edu.au](mailto:cdobler@med.usyd.edu.au)

Short Title: Tuberculosis in diabetes

Key words: tuberculosis, diabetes mellitus, relative risk, data linkage

Word count: 3,030

## Abstract

**Objective** Previous studies that have found an increased risk for tuberculosis (TB) in people with diabetes mellitus (DM) have been conducted in segments of the population and have not adjusted for important potential confounders. We sought to determine the relative risk for TB in the presence of DM in a national population with data on confounding factors in order to inform the decision making process about latent tuberculosis infection (LTBI) screening in people with diabetes.

**Design** Whole population historical cohort study

**Setting** All Australian States and Territories with a mean TB incidence of 5.8/100,000

**Participants** Cases of TB in people with DM were identified by record linkage using the National Diabetes Services Scheme database and TB notification databases for the years 2001 to 2006.

**Primary and secondary outcome measures** Primary outcome was notified cases of TB. Secondary outcome was notified cases of culture-confirmed TB. Relative risk of TB was estimated with adjustment for age, sex, TB incidence in country of birth and indigenous status.

**Results** There were 6276 cases of active TB among 19,855,283 people living in Australia between 2001 and 2006. There were 271 (188 culture positive) cases of TB among 802,087 members of the DM cohort and 130 cases of TB among 273,023 people using insulin. The crude relative risk (RR) of TB was 1.78 (95% CI 1.17 to 2.73) in all people with DM and 2.16 (95% CI 1.19 to 3.93) in people with DM using insulin. The adjusted relative risks were 1.48 (95% CI 1.04 to 2.10) and 2.27 (95% CI 1.41 to 3.66), respectively.

1  
2  
3 **Conclusions** The presence of DM alone does not justify screening for LTBI. However, when  
4  
5 combined with other risk factors for TB, the presence of DM may be sufficient to justify  
6  
7 screening and treatment for LTBI.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Article Summary

### Article focus

- National, general population-based, historical cohort study to estimate the risk of tuberculosis among people with diabetes mellitus.
- Adjustment for important potentially confounding risk factors including age, sex, indigenous status, and tuberculosis incidence in country of birth.

### Key messages

- Overall, people with diabetes mellitus have a 1.5 fold increased risk of developing tuberculosis.
- The risk for tuberculosis is higher among people who are using insulin for diabetes mellitus.
- Diabetes mellitus accounts for a small proportion of cases of tuberculosis in a low tuberculosis incidence setting.

### Strengths and limitations of this study

- The strengths of this study are the cohort design, the large population size, the general population base for the study cohort and the adjustment for important potential confounders, especially TB incidence in the country of birth.
- The study limitations are the unavailability of laboratory results to indicate if blood glucose levels were well or poorly controlled in people with diabetes mellitus and the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

inability to reliably distinguish between type 1 and type 2 diabetes mellitus in this data source.

For peer review only



## Introduction

Tuberculosis (TB) continues to be a major global health problem. It is estimated that one-third of the world's population have TB infection and there are 9.4 million new cases of TB per year.<sup>1</sup> Major impairment of cell-mediated immunity, such as occurs in HIV infection, leads to a dramatic increase in the risk of developing TB.<sup>2</sup> A lesser degree of impairment of immune function, such as occurs in patients with rheumatic diseases who are on moderate-to-high dose steroid treatment, has also been found to be associated with an increased TB risk.<sup>3</sup> Diabetes mellitus (DM) is a common chronic disease associated with impaired immune function. Cohort and case control studies have shown an association between DM and TB.<sup>4-9</sup> With the rising prevalence of DM in countries where TB is endemic, there has been renewed interest in the question of whether DM increases the risk of active TB, and thus could significantly add to the worldwide burden of disease.

A meta-analysis of cohort studies conducted in 2008 showed that DM was associated with an increased risk of TB (relative risk 3.11, 95% CI 2.27 to 4.26).<sup>10</sup> However, this finding was based on only three cohort studies, two of which were conducted in renal transplant recipients, who had another powerful cause of immunosuppression.<sup>11-12</sup> It did include one general population cohort study, conducted among South Korean civil servants, which identified an increased risk of TB among people with DM.<sup>5</sup> Findings from case-control studies were heterogeneous with odds ratios ranging from 1.16 to 7.83.<sup>10</sup> Most of these case-control studies did not measure or control adequately for potential major confounders.<sup>10</sup> Hence, the findings of these case-control studies may not be a valid reflection of the true risk of TB in association with DM. Another cohort study, also from East Asia but not included in the meta-analysis, found that DM was associated with a modest increase in the risk of active, culture-confirmed, and pulmonary TB, with adjusted hazard ratios of 1.8, 1.9 and 1.9

1  
2  
3 respectively.<sup>4</sup> An English study published in 2010 found a two- to threefold increased risk of  
4  
5 TB among patients admitted to hospital because of diabetes<sup>9</sup>.  
6  
7

8  
9  
10 With the growing epidemic of obesity and DM worldwide and continued high prevalence of  
11  
12 TB in low-income countries,<sup>13-14</sup> it is important to obtain further data on the relative risk of  
13  
14 TB in DM. We conducted a national, general population historical cohort study to estimate  
15  
16 the risk of TB among people with DM with adjustment for important potentially confounding  
17  
18 risk factors.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Setting and cohort

We conducted a national, general population historical cohort study among all 19.9 million residents of Australia, 802,087 (4.0%) of whom were registered with the National Diabetes Services Scheme (NDSS). Australia has a low incidence of TB (5.8 per 100,000 population) and 86% of all TB cases occur in overseas-born people.<sup>15</sup> All TB treatment is provided free of charge.

### Description of data sources and data linkage

#### National Diabetes Services Scheme

People with DM were identified using the National Diabetes Services Scheme (NDSS) database. The NDSS is a subsidy scheme operated by Diabetes Australia Ltd for the Australian Government. People who are registered with the NDSS can access a range of products including blood and urine testing strips, syringes, needles and insulin pump consumables at a concessional price. In order to register with the NDSS, an individual must receive certification of a diagnosis of DM and, if relevant, the need for insulin therapy, from a doctor or credentialed diabetes educator.<sup>16</sup> Access to diagnostic services is enhanced by the existence of a universal health insurance system which gives access to primary care and other health services free-of-charge or at low cost to all. People with all types of diabetes mellitus (type 1, type 2, gestational diabetes) are eligible for registration with the NDSS. Diabetes type is self-reported by the patients at the time of registration and confirmed by a health professional. We included all subjects into the analyses that were registered with the NDSS between January 2001 and December 2006 except those with gestational diabetes. Data on names, sex, State or Territory of usual residence, date of birth, country of birth, indigenous

1  
2  
3 status and insulin use were extracted and sent to the database manager who performed the  
4  
5 data linkage (see below).  
6  
7  
8

### 9 10 **State and Territory TB notification databases**

11 Notification of TB is compulsory in Australia as this notification initiates public health  
12  
13 investigation and action. All TB cases are collected at State and Territory level. We used the  
14  
15 State and Territory TB notification databases to identify patients with TB. All subjects that  
16  
17 were notified for active TB disease to one of the State or Territory TB notification databases  
18  
19 between January 2001 and December 2006 were included in our analyses. Data on names,  
20  
21 date of notification, date of birth, sex, country of birth, indigenous status and TB culture  
22  
23 results were extracted for this analysis.  
24  
25  
26  
27  
28

### 29 30 **Data linkage**

31  
32 People with DM who had an episode of active TB were identified by record linkage using the  
33  
34 NDSS database and the State and Territory TB notification databases from January 2001 to  
35  
36 December 2006. The linkage was performed at the Australian Institute of Health and Welfare  
37  
38 (AIHW). From the two datasets, match files were created containing a unique record  
39  
40 identifier, the data linkage items (surname, given names and date of birth) and the data  
41  
42 linkage check items (sex, country of birth, state/territory of residence). From each of the  
43  
44 original datasets, analysis files were created containing the unique record identifier and all the  
45  
46 data fields required for analysis. Each of the analysis files was then linked to the match files  
47  
48 and the record identifiers were removed from these analysis files. The data linkage also  
49  
50 allowed exclusion of duplicate data on the same patient. The data linkage protocol from the  
51  
52 AIHW has been published online.<sup>17</sup>  
53  
54  
55  
56  
57  
58  
59  
60

### Census data for the general population

Estimates for the distribution of age group, country of birth, sex, and indigenous status in the general population were obtained from the Australian Bureau of Statistics based on census data for 2006.

### Sample size and study power

The annual incidence of TB in Australia is 5.8 per 100,000. Hence, over six years, the expected cumulative incidence is 35 per 100,000. The study population is the entire population of Australia, that is, 20 million people. We estimated that there were 1,000,000 persons with diabetes. The study had 80% power to detect a relative risk of 1.16 or higher.

### Statistical analysis

Only cases of TB that were notified after DM was diagnosed were included. The follow-up period started from 1/1/2001 or the date of DM diagnosis, whichever was the later and continued until 31/12/2006 or the date of diagnosis of TB, whichever was the earlier. TB incidence rates were expressed per 100,000 person years of follow up with asymptotic 95% confidence intervals.<sup>18</sup>

The relative risk of TB in patients with DM was estimated using a log-binomial model with correction for overdispersion to prevent under-estimation of standard errors due to heterogeneity in the data. The model was adjusted for TB incidence in country of birth, sex, age and indigenous status. Individual level data on these potential confounders were available for the DM and TB cohorts. For the general population aggregate population data for these covariates were obtained from the Australian Bureau of Statistics in the form of a contingency table containing population numbers cross-classified by all possible

1  
2  
3 combinations of strata of the covariates listed above. Age was classified into 5 year age  
4  
5 groups and country of birth was aggregated to groupings of countries with a similar incidence  
6  
7 of TB (<10, 10-24, 25-49, 50-99, 100-299, and  $\geq 300$  per 100,000) based on published World  
8  
9 Health Organization data.<sup>19</sup>  
10

11  
12  
13  
14 Population attributable fraction was estimated using the formula:  $(Pe * (RR - 1)) / ((Pe * (RR$   
15  
16  $- 1) + 1)$  where RR is the relative risk, estimated as above, and Pe is the proportion of the  
17  
18 population exposed to the risk factor, that is, the prevalence of DM in the population.<sup>20</sup>  
19  
20

21  
22  
23 We performed planned sub-group analyses based on insulin treatment status and TB culture  
24  
25 status. In addition, interactions between DM status and age, sex, indigenous status, and TB  
26  
27 incidence in country of birth were tested.  
28  
29

30  
31  
32 All statistical analyses were carried out using SAS Statistical Software (Version 9.2) (SAS  
33  
34 Institute, Cary, NC, USA).  
35  
36

### 37 38 **Ethical approval**

39  
40 The study protocol was approved by the Sydney South West Area Health Service Human  
41  
42 Research Ethics Committee - Western Zone, the New South Wales Population & Health  
43  
44 Services Research Ethics Committee, the Australian Institute of Health and Welfare Ethics  
45  
46 Committee, the Queensland Health Research Ethics & Governance Unit, the Department of  
47  
48 Human Services Victoria Research Governance, the Australian Capital Territory Health  
49  
50 Human Research Ethics Committee, the Department of Health Western Australia Human  
51  
52 Research Ethics Committee, the Tasmania Health and Medical Human Research Ethics  
53  
54 Committee, the South Australia Department of Health Human Research Ethics Committee  
55  
56  
57  
58  
59  
60

1  
2  
3 and the Northern Territory Human Research Ethics Committee. The requirement for written  
4  
5 or verbal patients' consent for this data linkage study was waived by all of the above ethics  
6  
7 committees because existing data sources were used.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Results

The study population comprised 19,855,283 residents of Australia, 802,087 (4%) of whom were registered with the NDSS including 273,023 (1.4%) with DM who were using insulin.

Characteristics of the DM population, the general population, the TB population and the DM population with TB are shown in Table 1. The percentage of Australian-born people was slightly higher in the DM population than in the general population (74% versus 71%) and more people came from an area with a TB incidence below 25 / 100,000 (92% versus 84%). The mean duration of follow-up was 4.6 years.

There were 6,276 TB notifications (5.7/100,000 per year, 95% CI 5.5 to 5.8) in Australia during the study period (Table 2). There were 271 cases of TB among 802,087 members of the DM cohort (7.4/100,000 per year, 95% CI 6.5 to 8.3). Of these, 188 (69%) were culture positive, which is similar to the 70% culture positive cases among all TB notifications. There were 130 TB notifications among 273,023 people using insulin (9.1 per 100,000 per year, 95% CI 7.6 to 10.9).

The crude relative risk (RR) of TB was 1.78 (95% CI 1.17 to 2.73) in all people with DM and 2.16 (95% CI 1.19 to 3.93) in people with DM using insulin. In the multivariate analysis adjusted for age, TB incidence in country of birth, indigenous status and sex, the relative risk (aRR) of TB was 1.48 (95% CI 1.04 to 2.10) in all people with DM and 2.27 (95% CI 1.41 to 3.66) in people using insulin (Table 3). The estimates of relative risk were slightly higher when the analysis was limited to culture-confirmed cases of TB (Table 3).

The relative risks were not significantly modified by age group, indigenous status, sex or incidence in country of birth (all P values for interaction > 0.25).



1  
2  
3  
4  
5 The population attributable fraction of DM for TB was 1.7%, based on a diabetes prevalence  
6  
7 of 3.6%.<sup>21</sup>  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Discussion

In this large, population-based cohort study conducted in 19.9 million residents of Australia with adjustment for important confounding factors, we found that, overall, people with DM have a 1.5 fold increased risk of developing TB. Those who are using insulin for DM have a greater risk. We also found that the population attributable fraction of DM for TB was very small.

The results of our study extend the findings of previous studies, which have also observed an increased risk for TB in patients with DM. A cohort study in Hong Kong, limited to people aged 65 years or more, found an adjusted hazard ratio (aHR) of 1.77 (95% CI 1.41-2.24) for active TB, and an aHR of 1.91 (95% CI 1.45-2.52) for culture-confirmed TB among patients with DM.<sup>4</sup> However, this study found that people with diagnosed DM and with haemoglobin HbA1c <7% at enrolment were not at increased risk of TB (aHR 0.68, 95% CI 0.33 to 1.36). A Korean cohort study conducted in 790,000 civil servants found a RR of 3.47 (95% CI 2.98 to 4.03) for pulmonary TB in people with DM (and a RR of 5.15 for culture confirmed cases, 95% CI 3.82 to 6.94).<sup>5</sup> In the Korean study, a diagnosis of DM was based solely on blood glucose levels. Thus, it did not include diabetic subjects who were euglycaemic at the time of screening. In their systematic review on thirteen observational studies on the risk of DM in TB, Jeon et al. found that studies which used laboratory testing as the basis for the diagnosis of DM had a higher RR for TB than those that used self reporting or medical records (RR of 3.89, 2.26, and 1.61, respectively).<sup>10</sup> If blood glucose levels are used for the definition of DM patients with diabetes who have well controlled glucose levels are less likely to be included. These findings imply that hyperglycaemia, rather than a DM diagnosis per se, increases the risk of developing active TB. This is supported by the observation by Leung et al. that patients with poor recent glycaemic control as evidenced by a haemoglobin HbA1c  $\geq$ 7% had

1  
2  
3 a significantly increased risk of TB (adjusted hazard ratio (aHR) 2.56, 95% CI 1.95 to 3.35),  
4 while those with a haemoglobin HbA1c <7% did not (aHR 0.81, 95% CI 0.44 to 1.48).<sup>4</sup> In  
5  
6  
7 our study, DM diagnosis was based on self reporting confirmed by a health professional, and  
8  
9  
10 laboratory results were not available. As insulin use is often a marker of longer duration  
11  
12 and/or poorly controlled (type 2) DM, our finding that insulin users had a higher TB risk than  
13  
14 the whole diabetes cohort, would support the assumption that hyperglycaemia increases the  
15  
16 risk for developing active TB. However, as we did not have any data on duration of DM or  
17  
18 HbA1C levels, and people with type I diabetes were included in the insulin treated group, it  
19  
20 remains unclear whether insulin use is an independent risk factor for TB or a proxy for longer  
21  
22 duration or greater severity of DM.  
23  
24

25  
26  
27 Age did not modify the effect of DM on risk of TB in our study. Two published studies have  
28  
29 demonstrated stronger associations of DM with TB among people aged less than 40 years  
30  
31 compared with older people<sup>5,8</sup> In these studies the definition of DM cases was based on  
32  
33 laboratory results. Another study, which had a DM diagnosis based on medical records, did  
34  
35 not show the same trend for age.<sup>22</sup>  
36  
37  
38

39  
40 Interestingly, there is some evidence that the strength of the association of DM and TB  
41  
42 increases with increasing background TB incidence in the study population.<sup>7,10</sup> This trend  
43  
44 was found in a systematic review on the risk of TB in DM in 13 observational studies<sup>10</sup>, and  
45  
46 in a Texan study that found that the association was stronger for the population in the Texas  
47  
48 border region, where there are higher incidence rates of TB, compared with non-border  
49  
50 counties.<sup>7</sup> The reason for this observation is not entirely clear, but it could well relate to the  
51  
52 level of glucose control in patients with DM in settings with a high TB incidence.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The strengths of our study are the cohort design, the large population size and the general  
4 population base for the study cohort. We believe that the diabetes cohort represents a  
5 virtually complete cohort of patients with diagnosed diabetes in Australia. The Australian  
6 Diabetes, Obesity and Lifestyle Study (1999-2000), which included previously undiagnosed  
7 cases identified by blood glucose estimations, estimated that 950,000 persons aged 25 years  
8 and over had diabetes.<sup>23</sup> The National Health Survey 2004-05 found that 700,000 (3.6%)  
9 Australians identified themselves as having DM.<sup>21</sup> In the same period, 733,000 (3.6%)  
10 Australians with a certified diagnosis of DM were registered with the NDSS.<sup>21</sup> On the basis  
11 of these and other data, Diabetes Australia estimates that the NDSS covers 80%–90% of  
12 people with diagnosed DM.<sup>21</sup> The Australian Institute of Health and Welfare (AIHW) has  
13 identified the NDSS as one of the best available sources for monitoring the prevalence of  
14 diagnosed DM in Australia, based on coverage of the DM population, currency of the data  
15 source, and frequency of updates to the data source.<sup>21</sup> However, we acknowledge that the  
16 findings of this study may not be generalisable to people with undiagnosed DM, who may  
17 have an elevated risk of TB compared to those truly without diabetes.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Ascertainment of cases of TB is likely to be complete. TB is a notifiable disease in Australia  
39 and notification by hospitals, doctors, TB clinics and pathology laboratories leads to public  
40 health action. The rate of undiagnosed TB in Australia is assumed to be very low as all  
41 investigations and treatment related to TB are provided free of charge for everybody,  
42 independent of insurance and immigration status, thus lowering the threshold to access care.  
43  
44  
45  
46  
47  
48  
49  
50

51 An additional strength of this study is the adjustment for important potential confounders,  
52 especially for the TB incidence in the country of birth. The incidence of TB in the country of  
53 birth is one of the strongest predictors of the risk of developing TB, but none of the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 previously published studies had adjusted the RR for this important confounder.<sup>10</sup> This  
4  
5 adjustment is especially important for settings with a low incidence of TB, where the  
6  
7 majority of TB cases usually occur in foreign-born people.<sup>24</sup> The adjustment for the incidence  
8  
9 of TB in country of birth also makes the study results generalisable to populations with  
10  
11 varying incidence of TB.  
12

13  
14  
15  
16 Our study has some limitations. As outlined above, laboratory results were not available to  
17  
18 indicate if blood glucose levels were well or poorly controlled in people with DM. However,  
19  
20 the diagnosis of DM in this study population is robust as all individuals registered with the  
21  
22 NDSS must receive certification of a diagnosis of DM by a doctor or a credentialed diabetes  
23  
24 educator. The available data did not allow us to reliably distinguish between type 1 and type  
25  
26 2 DM. It did allow us to reliably distinguish between patients treated with insulin and those  
27  
28 not treated with insulin.  
29  
30  
31

32  
33  
34 Although, as described above, we did adjust for potential confounding due to the major risk  
35  
36 factors for TB in Australia, we did not have information on socioeconomic status, which may  
37  
38 have been a confounding factor in this setting. A limitation that this study shares with  
39  
40 previously published papers in this area is that we did not have any information on treatment  
41  
42 of latent tuberculosis infection in the NDSS cohort. However, routine assessment and  
43  
44 treatment for latent tuberculosis infection in patients with diabetes is currently not  
45  
46 recommended in Australia, and it can therefore be assumed that most people with diabetes  
47  
48 would not have been assessed and treated for latent tuberculosis infection.  
49  
50

## 51 52 53 54 **Conclusions** 55 56 57 58 59 60

1  
2  
3 DM is associated with a modest increase in the risk of developing TB. The risk is greater  
4  
5 among those treated with insulin for diabetes. Based on this modest relative risk, the presence  
6  
7 of DM alone does not justify screening for, and treatment of, latent tuberculosis infection  
8  
9 (LTBI). However, when combined with other risk factors for TB, the presence of DM may be  
10  
11 sufficient to justify screening and treatment for LTBI. The low population attributable risk, at  
12  
13 least in Australia, suggests that control of TB in people with DM is unlikely to make a major  
14  
15 contribution to the burden of TB in the population.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments

We acknowledge Mark Short, PhD, BSc (Hons) and David Meere, BSc, from the Australian Institute of Health and Welfare for performing the database linkage. We also acknowledge the numerous people who have contributed to the collection of TB notifications and the maintenance of TB notification databases in all Australian States and Territories and the National Diabetes Services Scheme which granted us access to their database.

## Financial disclosure

The study was funded by a grant from the Sydney South West Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Author contributions

All authors were involved in study concept and design, acquired data, revised the manuscript for important content, and approved the final manuscript. CCD drafted the manuscript. GBM performed the statistical analysis.

## Competing interests

No conflict of interest reported.

## Data sharing statement

There are no data available for sharing.

## Trial registration

Trial registration was not required, as this was a historical cohort study

## References

1. World Health Organization. Global tuberculosis control: WHO report. 2010. [http://www.who.int/tb/publications/global\\_report/2010/en/index.html](http://www.who.int/tb/publications/global_report/2010/en/index.html) Accessed November 11, 2011.
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* 2003;163:1009-1021.
3. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. *Clin Exp Rheumatol* 1998;16:9-13.
4. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. *Am J Epidemiol* 2008;167:1486-1494.
5. Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. *Tuber Lung Dis* 1995;76:529-533.
6. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. *Am J Public Health* 1997;87:574-579.
7. Perez A, Brown HS, 3rd, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. *Am J Trop Med Hyg* 2006;74:604-611.
8. Ponce-De-Leon A, Garcia-Garcia Md MdL, Garcia-Sancho MC, et al. Tuberculosis and diabetes in southern Mexico. *Diabetes Care* 2004;27:1584-1590.
9. Young F, Wotton CJ, Critchley JA, et al. Increased risk of tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. *J Epidemiol Community Health* 2010 (epub ahead of print).
10. Jeon CY, Murray MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. *PLoS Med* 2008;5:e152.
11. Chen CH, Lian JD, Cheng CH, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. *Transpl Infect Dis* 2006;8:148-156.
12. John GT, Shankar V, Abraham AM, et al. Risk factors for post-transplant tuberculosis. *Kidney Int* 2001;60:1148-1153.
13. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 2009;301:2129-2140.
14. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;9:737-746.



15. Barry C, Konstantinos A. Tuberculosis notifications in Australia, 2007. *Commun Dis Intell* 2009;33:304-315.
16. Process for Registration with the NDDS. <http://www.ndss.com.au/>. Accessed November 11, 2011.
17. AIHW. Data linkage and protecting privacy: a protocol for linking between two or more data sets held within the Australian Institute of Health and Welfare. [http://www.aihw.gov.au/dataonline/aihw\\_privacy\\_protection\\_protocols\\_data\\_linkage.pdf](http://www.aihw.gov.au/dataonline/aihw_privacy_protection_protocols_data_linkage.pdf) Accessed November 11, 2011.
18. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981. p. 14-5.
19. World Health Organization. Global Tuberculosis database. <http://apps.who.int/globalatlas/dataQuery/default.asp> Accessed November 11, 2011.
20. Walter SD. Calculation of attributable risks from epidemiological data. *Int J Epidemiol* 1978;7:175-182.
21. Australian Institute of Health and Welfare 2009. Diabetes prevalence in Australia: an assessment of national data sources. Diabetes series no. 14. Cat. no. CVD 46. Canberra: AIHW. <http://www.aihw.gov.au/publications/index.cfm/title/10639>. Accessed November 11, 2011.
22. Dyck RF, Klomp H, Marciniuk DD, et al. The relationship between diabetes and tuberculosis in Saskatchewan: comparison of registered Indians and other Saskatchewan people. *Can J Public Health* 2007;98:55-59.
23. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care* 2002;25:829-834.
24. Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. *JAMA* 2008;300:405-412.

**Tables****Table 1.** Characteristics of the general population, the DM population, the TB population and the TB in DM population

Variable	General population excluding people with diabetes (n=19,053,196)	DM population (n=802,087)	TB population (n=6,276)	TB in DM population (n=271)
<b>Gender, number (%)</b>				
Female	9,669,609 (51)	386,427 (48)	3045 (49)	122 (45)
Male	9,383,587 (49)	415,660 (52)	3231 (51)	149 (55)
<b>Age group in years, number (%)</b>				
<15	3,931,189 (21)	6,024 (1)	272 (4)	0
15-34	5,341,173 (28)	39,482 (5)	2220 (35)	10 (4)
35-54	5,526,963 (29)	173,391 (21)	1729 (28)	56 (21)
55-74	3,199,578 (17)	366,534 (46)	1176 (19)	123 (45)
≥ 75	1,054,293 (6)	216,656 (27)	879 (14)	82 (30)
<b>Country of origin, number (%)</b>				
Australian born	13,477,425 (71)	595,518 (74)	1212 (19)	131 (48)
born overseas	4,209,464 (22)	206,569 (26)	5064 (81)	140 (52)
unknown	1,366,307 (7)	0	0	0
<b>Indigenous status, number (%)</b>				
non-indigenous or not-stated	18,622,238 (98)	780,197 (97)	6072 (97)	265(98)
indigenous	430,958 (2)	21,890 (3)	204 (3)	6 (2)
<b>TB incidence in country of birth (per 100,000), number (%)</b>				
<25	16,052,757 (84)	739,423 (92)	1964 (31)	168 (62)
25-99	848,417 (4)	36,292 (5)	1350 (22)	44 (16)
≥100	728,119 (4)	26372 (3)	2962 (47)	59 (22)
unknown	1,423,903 (7)	0	0	0

**Table 2.** Crude incidence of tuberculosis in the general population and in people with diabetes

	Incidence of all TB per 100,000/year (95% confidence interval)		Incidence of culture positive TB per 100,000/year (95% confidence interval)	
	General population	People with diabetes	General population	People with diabetes
<b>All persons</b>	5.7 (5.5 to 5.8)	7.4 (6.5 to 8.3)	4.0 (3.9 to 4.1)	5.1 (4.4 to 5.9)
<b>Age, years</b>				
<15	1.2 (1.1 to 1.4)	0	0.4 (0.3 to 0.5)	0
15 to 34	7.4 (7.1 to 7.7)	6.1 (3.1 to 11.7)	5.5 (5.2 to 5.8)	4.3 (1.9 to 9.3)
35 to 54	5.5 (5.2 to 5.7)	7.5 (5.8 to 9.9)	3.9 (3.7 to 4.1)	5.5 (4.0 to 7.6)
55 to 74	6.0 (5.6 to 6.3)	7.4 (6.2 to 8.9)	4.1 (3.8 to 4.4)	4.9 (3.9 to 6.1)
≥ 75	13.0 (12.1 to 13.9)	7.5 (6.0 to 9.4)	9.7 (9.0 to 10.5)	5.4 (4.2 to 7.0)
<b>Sex</b>				
Male	5.9 (5.7 to 6.2)	7.9 (6.7 to 9.3)	4.3 (4.1 to 4.5)	5.4 (4.4 to 6.6)
Female	5.4 (5.2 to 5.6)	6.9 (5.7 to 8.3)	3.7 (3.6 to 4.9)	4.9 (3.9 to 6.0)
<b>TB incidence in country of birth</b>				
< 25 per 100,000	1.95 (1.86 to 2.04)	4.9 (4.2 to 5.7)	1.26 (1.20 to 1.34)	3.4 (2.8 to 4.1)
25-99 per 100,000	25.5 (24.1 to 26.9)	30.1 (22.1 to 40.8)	18.0 (16.9 to 19.2)	18.5 (12.4 to 27.3)
≥100 per 100,000	65.4 (63.1 to 67.8)	57.8 (44.4 to 75.0)	48.8 (46.8 to 50.9)	45.0 (33.3 to 60.6)

**Table 3.** Relative Risks (crude and adjusted) for different TB endpoints

Characteristics	Crude Relative Risk univariate analysis (95% CI)	p value	Adjusted Relative Risk <sup>a</sup> multivariate analysis (95% CI)	p value
All TB	1.78 (1.17 to 2.73)	0.008	1.48 (1.04 to 2.10)	0.03
Culture positive TB	1.83 (1.19 to 2.81)	0.006	1.49 (1.05 to 2.11)	0.02
All TB in insulin-users	2.16 (1.19 to 3.93)	0.01	2.27 (1.41 to 3.66)	0.0008
Culture positive TB in insulin-users	2.44 (1.37 to 4.34)	0.002	2.55 (1.62 to 4.01)	<0.001

a Adjusted for sex, age, indigenous status, TB incidence in country of birth

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9-10
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	Data linkage, not clinical trial
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Data linkage, not clinical trial See above See above
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	12+ Table1 NA 12
Outcome data	15*	Report numbers of outcome events or summary measures over time	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	12, Table 2+3 Table 2
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	14
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	16-17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>